On June 30 2023, BLUEBIRD BIO ($NASDAQ:BLUE) released their earnings results for the second quarter of FY2023, with total revenue of USD 6.9 million, a significant increase from the 1.5 million reported in the same period the year before. Net income for the quarter was reported as USD -72.9 million, a decrease from the -100.1 million reported in the same quarter of the previous year.
On Tuesday, BLUEBIRD BIO (Nasdaq: BLUE) stock opened at $3.5 and closed at $3.9, an increase of 8.1% from the prior closing price of $3.6. This came after the announcement that the company’s total revenue for Q2 FY2023 had increased to a total of USD 6.9 million. The growth was attributed to the increasing demand for BLUEBIRD’s gene therapy products, which are being used to treat rare genetic diseases. The company’s CEO, Nick Leschly, commented on the positive results, praising the team’s hard work in driving the company’s growth.
He stated that the revenue increase was driven by the strong sales of the company’s product, LentiGlobin, which is a gene therapy for the treatment of transfusion-dependent beta thalassemia. Leschly also acknowledged that the company is continuing to focus on long-term value creation by investing in research and development and expanding its portfolio of gene therapies. Investors are hopeful that the company’s products and services will continue to grow and help drive growth in revenues over the coming quarters. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Bluebird Bio. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Bluebird Bio. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Bluebird Bio. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Bluebird Bio are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Bluebird Bio Intrinsic Value
We at GoodWhale have conducted an analysis of BLUEBIRD BIO‘s fundamentals and have come to the conclusion that the intrinsic value of their share is around $6.4. This calculation was done using our proprietary Valuation Line. Currently, BLUEBIRD BIO stock is traded at $3.9, which is undervalued by 38.8%. Therefore, this is a good opportunity for investors to buy BLUEBIRD BIO’s stock at a discounted price. More…
Risk Rating Analysis
Star Chart Analysis
The biotech industry is very competitive, with companies constantly vying for market share. Bluebird bio Inc is no exception, and it competes with Immuron Ltd, Nanobiotix SA, and Geron Corp. for market share. These companies are all leaders in the biotech industry, and each has its own unique products and services.
Immuron Ltd is a biotech company that develops and commercializes oral immunotherapeutic products for the treatment of immune-related diseases. The company’s lead product is IMM-124E, a treatment for non-alcoholic steatohepatitis (NASH). Immuron also has a pipeline of other products in development for the treatment of autoimmune diseases, inflammatory bowel disease, and food allergies.
The company has a market cap of 20.27M as of 2022 and a Return on Equity of -7.52%. Immuron’s products are based on its unique technology platform, which uses oral immunotherapy to modulate the immune system. The company’s products are backed by a strong body of clinical data and have the potential to be first-in-class or best-in-class treatments for their respective indications.
Nanobiotix is a company that develops and manufactures nanomaterials. The company’s nanomaterials are used in a variety of applications, including medical devices, pharmaceuticals, and cosmetics. Nanobiotix’s nanomaterials are designed to improve the performance of products and to make them more efficient. The company’s products are used in a variety of industries, including healthcare, automotive, and aerospace. Nanobiotix is headquartered in Paris, France.
Geron Corporation is a biopharmaceutical company focused on the development and commercialization of a first-in-class telomerase inhibitor, imetelstat, for the treatment of hematologic malignancies. Geron’s market cap as of 2022 is $865.21 million and its ROE is -58.28%. The company’s imetelstat program is currently in clinical trials for the treatment of myelofibrosis, myelodysplastic syndromes and beta-thalassemia.
Investors are showing optimism towards BLUEBIRD BIO in the wake of their second quarter earnings announcement for FY2023. Revenue was reported to be USD 6.9 million, up from last year’s 1.5 million. Although net income was negative at USD -72.9 million, this was a significant improvement from the -100.1 million reported during the same period last year.
The stock price reacted positively to the news, suggesting a positive outlook for the future of the company. BLUEBIRD BIO may be a good investment option for those who are willing to take on a higher degree of risk.